Actively Recruiting

Age: 18Years - 90Years
All Genders
NCT07363811

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Led by Necmettin Erbakan University · Updated on 2026-01-26

50

Participants Needed

1

Research Sites

100 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.

CONDITIONS

Official Title

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological and staging diagnosis of metastatic non-small cell lung cancer
  • ECOG performance score between 0 and 2
  • No contraindications for nivolumab
Not Eligible

You will not qualify if you...

  • Patients diagnosed with metastatic NSCLC who received nivolumab as adjuvant or perioperative therapy
  • Patients with a second primary malignancy undergoing active treatment
  • Patients who have not signed the informed consent form
  • Patients with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome
  • Patients who have undergone palliative or curative radiotherapy within the last three months
  • Patients with active viral or bacterial infections before nivolumab treatment
  • Patients who have used steroids in the last three months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology

Konya, Meram, Turkey (Türkiye), 42090

Actively Recruiting

Loading map...

Research Team

A

Ahmet Oruç MD

CONTACT

M

Mehmet Artaç MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here